Align Technology, Inc. (ALGN) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $178.47 (+1.40%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 25, 2026 | Glen Santangelo | Barclays | $200.00 | +12.1% |
| Feb 9, 2026 | Sidharth Sahoo | HSBC | $200.00 | +12.1% |
| Feb 5, 2026 | Elizabeth Anderson | Evercore ISI | $200.00 | +12.1% |
| Jan 20, 2026 | Steven Valiquette | Mizuho Securities | $200.00 | +12.1% |
| Oct 30, 2025 | Jonathan Block | Stifel Nicolaus | $200.00 | +12.1% |
| Oct 30, 2025 | Jason Bednar | Piper Sandler | $200.00 | +12.1% |
| Oct 23, 2025 | Jason Bednar | Piper Sandler | $190.00 | +6.5% |
| Oct 8, 2025 | Elizabeth Anderson | Evercore ISI | $160.00 | -10.3% |
| Oct 24, 2024 | Jonathan Block | Stifel Nicolaus | $275.00 | +54.1% |
| Oct 24, 2024 | Jason Bednar | Piper Sandler | $275.00 | +54.1% |
| Oct 24, 2024 | Michael Cherny | Leerink Partners | $235.00 | +31.7% |
| Oct 24, 2024 | Elizabeth Anderson | Evercore ISI | $250.00 | +40.1% |
| Oct 17, 2024 | Jason Bednar | Piper Sandler | $285.00 | +59.7% |
| Oct 11, 2024 | Jonathan Block | Stifel Nicolaus | $285.00 | +59.7% |
| Oct 10, 2024 | Charles Perron-Piche | Goldman Sachs | $225.00 | +26.1% |
| Oct 8, 2024 | Elizabeth Anderson | Evercore ISI | $270.00 | +51.3% |
| Jul 25, 2024 | Jason Bednar | Piper Sandler | $315.00 | +76.5% |
| Jul 22, 2024 | Jeff Johnson | Robert W. Baird | $325.00 | +82.1% |
| Jun 21, 2024 | Jason Bednar | Piper Sandler | $330.00 | +84.9% |
| Apr 25, 2024 | Jason Bednar | Piper Sandler | $375.00 | +110.1% |
Top Analysts Covering ALGN
ALGN vs Sector & Market
| Metric | ALGN | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.31 | 2.24 | 2.41 |
| Analyst Count | 13 | 8 | 18 |
| Target Upside | +14.1% | +1150.3% | +14.9% |
| P/E Ratio | 29.94 | 6.84 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $4.17B | $4.18B | $4.20B | 12 |
| 2027-03-31 | $1.05B | $1.06B | $1.08B | 4 |
| 2027-06-30 | $1.09B | $1.09B | $1.12B | 6 |
| 2027-09-30 | $1.06B | $1.07B | $1.09B | 4 |
| 2027-12-31 | $1.11B | $1.12B | $1.14B | 7 |
| 2028-03-31 | $1.11B | $1.12B | $1.14B | 3 |
| 2028-06-30 | $1.13B | $1.14B | $1.17B | 5 |
| 2028-09-30 | $1.11B | $1.12B | $1.14B | 3 |
| 2028-12-31 | $1.17B | $1.18B | $1.21B | 6 |
| 2029-12-31 | $4.85B | $4.90B | $5.00B | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $11.15 | $11.30 | $11.59 | 11 |
| 2027-03-31 | $2.49 | $2.52 | $2.59 | 3 |
| 2027-06-30 | $2.94 | $2.97 | $3.06 | 3 |
| 2027-09-30 | $3.10 | $3.13 | $3.22 | 4 |
| 2027-12-31 | $3.52 | $3.55 | $3.65 | 3 |
| 2028-03-31 | $2.58 | $2.60 | $2.68 | 4 |
| 2028-06-30 | $3.17 | $3.20 | $3.29 | 4 |
| 2028-09-30 | $3.18 | $3.21 | $3.30 | 6 |
| 2028-12-31 | $3.80 | $3.84 | $3.95 | 4 |
| 2029-12-31 | $15.53 | $15.71 | $16.15 | 2 |
Frequently Asked Questions
What is the analyst consensus for ALGN?
The consensus among 13 analysts covering Align Technology, Inc. (ALGN) is Buy with an average price target of $203.67.
What is the highest price target for ALGN?
The highest price target for ALGN is $790.00, set by Julien Ouaddour at BNP Paribas on 2021-07-08.
What is the lowest price target for ALGN?
The lowest price target for ALGN is $160.00, set by Elizabeth Anderson at Evercore ISI on 2025-10-08.
How many analysts cover ALGN?
13 analysts have issued ratings for Align Technology, Inc. in the past 12 months.
Is ALGN a buy or sell right now?
Based on 13 analyst ratings, ALGN has a consensus rating of Buy (2.31/5) with a +14.1% upside to the consensus target of $203.67.
What are the earnings estimates for ALGN?
Analysts estimate ALGN will report EPS of $11.30 for the period ending 2026-12-31, with revenue estimated at $4.18B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.